GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (NAS:INM) » Definitions » Insider Ownership

InMed Pharmaceuticals (InMed Pharmaceuticals) Insider Ownership : 4.86 % (As of Jun. 09, 2024)


View and export this data going back to . Start your Free Trial

What is InMed Pharmaceuticals Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, InMed Pharmaceuticals's insider ownership is 4.86%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, InMed Pharmaceuticals's Institutional Ownership is 0.01%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, InMed Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 99.93%.


InMed Pharmaceuticals Insider Ownership Historical Data

The historical data trend for InMed Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals Insider Ownership Chart

InMed Pharmaceuticals Historical Data

The historical data trend for InMed Pharmaceuticals can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Insider Ownership 12.08 12.08 6.09 6.09 6.09 6.09 6.70 6.70 6.70 4.86

InMed Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


InMed Pharmaceuticals (InMed Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
815 West Hastings Street, Suite 310, Vancouver, BC, CAN, V6C 1B4
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Executives
Jonathan Tegge officer: Interim CFO 217 W. MAIN STREET, SOMERVILLE NJ 08876
Sarah Li officer: VP, Accounting and Controller 310-815 WEST HASTINGS ST., VANCOUVER Z4 V6C1B4
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
Bryan T Baldasare director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric A Adams director, officer: President & CEO C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Brenda Edwards officer: Interim CFO 111-1232 JOHNSON ST., COQUITLAM A1 V3B 4T2
Janet P Grove director 510 WEST GEORGIA STREET, SUITE 1800, VANCOUVER A1 V5T 4T5
Bruce Colwill officer: CFO C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Shane Aaron Johnson officer: SVP & GM of BayMedica LLC 930 TAHOE BLVD., SUITE 802-433, INCLINE VILLAGE NV 89451
Adam D. Cutler director 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
William J Garner director 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010
Catherine Sazdanoff director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric C Hsu officer: Sr. VP, Pre-Clinical Res/Dev C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Michael Woudenberg officer: VP, Chem/Manufacturing/Control C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Mancini Alexandra Diane Janet officer: Sr VP, Clinical Reg Affairs C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4

InMed Pharmaceuticals (InMed Pharmaceuticals) Headlines

From GuruFocus

InMed Announces Results of 2022 Annual General Meeting

By Value_Insider Value_Insider 12-16-2022

InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria

By GlobeNewswire GlobeNewswire 08-23-2022

InMed Submits Form 12b-25

By GlobeNewswire GlobeNewswire 02-10-2023